Ocugen (NASDAQ: OCGN)
Ocugen Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Ocugen Company Info
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
News & Analysis
Why Ocugen Stock Zoomed 12% Higher Today
A peer across the Pacific Ocean has purchased the rights to one of the biotech's pipeline drugs.
Ocugen (OCGN) Q2 Revenue Jumps 20%
1 Stock That More Than Doubled This Year That I Wouldn't Touch With a 10-Foot Pole
Don't jump on the bandwaggon.
Can Ocugen Stock Keep Churning Higher?
This tiny biotech caught fire in 2024. Can it sustain the momentum?
Why Ocugen Stock Eked Out a Win Today
The company is clearly progressing on several fronts with its pipeline programs.
1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell
Ocugen has recently broadened its pipeline.
3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street
Select analysts expect these small-caps stocks to catapult higher in the new year.
Why Shares of Ocugen Jumped Thursday
Could short-sellers be enacting a squeeze?
Valuation
Earnings Transcripts
Ocugen (OCGN) Q4 2024 Earnings Call Transcript
OCGN earnings call for the period ending December 31, 2024.
Ocugen (OCGN) Q3 2024 Earnings Call Transcript
OCGN earnings call for the period ending September 30, 2024.
Ocugen (OCGN) Q2 2024 Earnings Call Transcript
OCGN earnings call for the period ending June 30, 2024.
Ocugen (OCGN) Q4 2023 Earnings Call Transcript
OCGN earnings call for the period ending March 31, 2024.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.